Endogenous estrogen and postmenopausal breast cancer: A quantitative review

Cancer Causes and Control

Volumn 8, Issue 6, 1997, Pages 922-928

  Thomas, Hollie V ^a,b   Reeves, Gillian K ^a   Key, Timothy J A ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b RADCLIFFE INFIRMARY   (United Kingdom)

Author keywords

Breast cancer; Estrogen; Postmenopausal; Review; Women

Indexed keywords

ESTRADIOL; ESTROGEN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; ESTROGEN URINE LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; QUANTITATIVE ASSAY;

AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CONFIDENCE INTERVALS; ESTRADIOL; ESTROGENS; FEMALE; HUMANS; INCIDENCE; MIDDLE AGED; ODDS RATIO; POSTMENOPAUSE; PROSPECTIVE STUDIES; RISK FACTORS; UNITED STATES;

EID: 0030666150     PISSN: 09575243     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018476631561     Document Type: Article

References (41)

1. Pike MC, Spicer DV, Dahmoush L, Press MF. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 1993; 15: 17-35.
2. Key TJ, Pike MC. The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer. Eur J Cancer Clin Oncol 1988; 24: 29-43.
3. Forrest APM. Concluding remarks. Proc Royal Soc Edinburgh 1989; 95B: 305-7.
4. Bernstein L, Ross RK, Pike MC, Brown JB, Henderson BE. Hormone levels in older women: a study of post-menopausal breast cancer patients and healthy population controls. Br J Cancer 1990; 61: 298-302.
5. Lemon HM, Wotiz HH, Parsons L, Mozden PJ. Reduced estriol excretion in patients with breast cancer prior to endocrine therapy. JAMA 1966; 196: 1128-36.
6. Krishnamoorthy G, Govindarajulu P, Ramalingam V. Serum hormones in human breast cancer subjects. Neoplasma 1989; 36: 221-31.
7. Ota DM, Jones LA, Jackson GL, Jackson PM, Kemp K, Bauman D. Obesity, non-protein-bound estradiol levels, and distribution of estradiol in the sera of breast cancer patients. Cancer 1986; 57: 558-62.
8. McFadyen IJ, Forrest AP, Prescott RJ, et al. Circulating hormone concentrations in women with breast cancer. Lancet 1976; i: 1100-2.
9. Argüelles AE, Poggi UL, Saborida C, Hoffman C, Chekherdemian M, Blanchard O. Endocrine profiles and breast cancer. Lancet 1973; i: 165-8.
10. Marmorston J, Crowley LG, Myers SM, Stern E, Hopkins CE. II. Urinary excretion of estrone, estradiol, and estriol by patients with breast cancer and benign breast disease. Am J Obst & Gynec 1965; 92: 460-7.
11. Grönroos M, Aho AJ. Estrogen metabolism in postmenopausal women with primary and recurrent breast cancer. Eur J Cancer 1968; 4: 523-7.
12. England PC, Skinner LG, Cottrell KM, Sellwood RA. Serum oestradiol-17 beta in women with benign and malignant breast disease. Br J Cancer 1974; 30: 571-6.
13. Morreal CE, Dao TL, Nemoto T, Lonergan PA. Urinary excretion of estrone, estradiol, and estriol in postmenopausal women with primary breast cancer. JNCI 1979; 63: 1171-4.
14. Reed MJ, Cheng RW, Noel CT, Dudley HA, James VH. Plasma levels of estrone, estrone sulfate, and estradiol and the percentage of unbound estradiol in postmenopausal women with and without breast disease. Cancer Res 1983; 43: 3940-3.
15. Bruning PF, Bonfrer JM, Hart AA. Non-protein bound oestradiol, sex hormone binding globulin, breast cancer and breast cancer risk. Br J Cancer 1985; 51: 479-84.
16. El-Aaser AA, El-Merzabani MM, Abu-Bedair FA. Serum estrogen level in Egyptian breast cancer patients. Tumori 1985; 71: 293-5.
17. Siiteri PK, Simberg N, Murai J. Estrogens and breast cancer. Ann N Y Acad Sci 1986; 464: 100-5.
18. The Anglo-Egyptian Health Agreement Collaborative Study. Serum hormone levels in breast cancer patients and controls in Egypt and Great Britain. The Anglo-Egyptian Health Agreement Collaborative Study. Eur J Cancer Clin Oncol 1988; 24: 1329-35.
19. Bennett IC, McCaffrey JF, McCaffrey E, Wyatt B. Serum oestradiol in women with and without breast disease [published erratum appears in Br J Cancer 1990; 62: 336]. Br J Cancer 1990; 61: 142-6.
20. Blankenstein MA, Szymczak J, Daroszewski J, Milewicz A, Thijssen JH. Estrogens in plasma and fatty tissue from breast cancer patients and women undergoing surgery for non-oncological reasons. Gynecol Endocrinol 1992; 6: 13-7.
21. Persson BH, Risholm L. Oophorectomy and cortisone treatment as a method of eliminating oestrogen production in patients with breast cancer. Acta Endocrinologica 1964; 47: 15-26.
22. Pearce S, Dowsett M, McKinna JA. Albumin-bound and non-protein-bound oestradiol and testosterone in postmenopausal breast disease. Eur J Cancer 1991; 27: 259-63.
23. Wysowski DK, Comstock GW, Helsing KJ, Lau HL. Sex hormone levels in serum in relation to the development of breast cancer. Am J Epidemiol 1987; 125: 791-9.
24. Garland CF, Friedlander NJ, Barrett-Connor E, Khaw KT. Sex hormones and postmenopausal breast cancer: a prospective study in an adult community. Am J Epidemiol 1992; 135: 1220-30.
25. Helzlsouer KJ, Alberg AJ, Bush TL, Longcope C, Gordon GB, Comstock GW. A prospective study of endogenous hormones and breast cancer. Cancer Detect Prev 1994; 18: 79-85.
26. Toniolo PG, Levitz M, Zeleniuch-Jacquotte A, et al. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. JNCI 1995; 87: 190-7.
27. Berrino F, Muti P, Micheli A, et al. Serum sex hormone levels after menopause and subsequent breast cancer. JNCI 1996; 88: 291-6.
28. Dorgan JF, Longcope C, Stephenson HE, et al. Relation of prediagnostic serum estrogen and androgen levels to breast cancer risk. Cancer Epidemiol Biomark Prev 1996; 5: 533-9.
29. Thomas HV, Key TJ, Allen DS, et al. A prospective study of endogenous serum hormone concentrations and breast cancer risk in postmenopausal women on the island of Guernsey. Br J Cancer 1997; 76: 401-5.
30. Moore JW, Clark GM, Bulbrook RD, et al. Serum concentrations of total and non-protein-bound oestradiol in patients with breast cancer and in normal controls. Int J Cancer 1982; 29: 17-21.
31. Jones LA, Ota DM, Jackson GA, et al. Bioavailability of estradiol as a marker for breast cancer risk assessment. Cancer Res 1987; 47: 5224-9.
32. Zaridze D, Kushlinskii N, Moore JW, Lifanova YE, Bassalyk L, Wang DY. Endogenous plasma sex hormones in pre- and postmenopausal women with breast cancer: results from a case-control study in Moscow. Eur J Cancer Prev 1992; 1: 225-30.
33. Grattarola R, Secreto G, Recchione C, Castellini W. Androgens in breast cancer. II. Endometrial adenocarcinoma and breast cancer in married postmenopausal women. Am J Obstet Gynecol 1974; 118: 173-8.
34. Key TJA, Wang DY, Brown JB, et al. A prospective study of urinary oestrogen excretion and breast cancer risk. Br J Cancer 1996; 73: 1615-9.
35. Thijssen JH, Poortman J, Schwarz F. Androgens in postmenopausal breast cancer: excretion, production and interaction with estrogens. J Steroid Biochem 1975; 6: 729-34.
36. Kuller LH, Gutai JP. Re: A prospective study of endogenous estrogens and breast cancer in postmenopausal women. JNCI 1995; 87: 1414-5.
37. Malarkey WB, Schroeder LL, Stevens VC, James AG, Lanese RR. Twenty-four-hour preoperative endocrine profiles in women with benign and malignant breast disease. Cancer Res 1977; 37: 4655-9.
38. Drafta D, Schindler AE, Milcu SM, et al. Plasma hormones in pre- and postmenopausal breast cancer. J Steroid Biochem 1980; 13: 793-802.
39. Bird CE, Cook S, Owen S, Sterns EE, Clark AF. Plasma concentrations of C-19 steroids, estrogens, FSH, LH and prolactin in post-menopausal women with and without breast cancer. Oncology 1981; 38: 365-8.
40. Secreto G, Recchione C, Cavalleri A, Miragha M, Dati V. Circulating levels of testosterone, 17 beta-oestradiol, luteinising hormone and prolactin in postmenopausal breast cancer patients. Br J Cancer 1983; 47: 269-75.
41. Reed MJ, Beranek PA, Cheng RW, Ghilchik MW, James VH. The distribution of oestradiol in plasma from postmenopausal women with or without breast cancer: relationships with metabolic clearance rates of oestradiol. Int J Cancer 1985; 35: 457-60.